6.
Ludwig S, Planz O, Pleschka S, Wolff T
. Influenza-virus-induced signaling cascades: targets for antiviral therapy?. Trends Mol Med. 2003; 9(2):46-52.
DOI: 10.1016/s1471-4914(02)00010-2.
View
7.
Hamza H, Shehata M, Mostafa A, Pleschka S, Planz O
. Improved Efficacy of Baloxavir Marboxil Against Influenza A Virus Infection by Combination Treatment With the MEK Inhibitor ATR-002. Front Microbiol. 2021; 12:611958.
PMC: 7928405.
DOI: 10.3389/fmicb.2021.611958.
View
8.
Antunes I, Kassiotis G
. Suppression of innate immune pathology by regulatory T cells during Influenza A virus infection of immunodeficient mice. J Virol. 2010; 84(24):12564-75.
PMC: 3004299.
DOI: 10.1128/JVI.01559-10.
View
9.
Planz O, Bilzer T, Sobbe M, Stitz L
. Lysis of major histocompatibility complex class I-bearing cells in Borna disease virus-induced degenerative encephalopathy. J Exp Med. 1993; 178(1):163-74.
PMC: 2191065.
DOI: 10.1084/jem.178.1.163.
View
10.
Gill J, Sheng Z, Ely S, Guinee D, Beasley M, Suh J
. Pulmonary pathologic findings of fatal 2009 pandemic influenza A/H1N1 viral infections. Arch Pathol Lab Med. 2010; 134(2):235-43.
PMC: 2819217.
DOI: 10.5858/134.2.235.
View
11.
Eggena M, Barugahare B, Jones N, Okello M, Mutalya S, Kityo C
. Depletion of regulatory T cells in HIV infection is associated with immune activation. J Immunol. 2005; 174(7):4407-14.
DOI: 10.4049/jimmunol.174.7.4407.
View
12.
Shafiani S, Tucker-Heard G, Kariyone A, Takatsu K, Urdahl K
. Pathogen-specific regulatory T cells delay the arrival of effector T cells in the lung during early tuberculosis. J Exp Med. 2010; 207(7):1409-20.
PMC: 2901066.
DOI: 10.1084/jem.20091885.
View
13.
Fox A, Le N, Horby P, van Doorn H, Nguyen V, Nguyen H
. Severe pandemic H1N1 2009 infection is associated with transient NK and T deficiency and aberrant CD8 responses. PLoS One. 2012; 7(2):e31535.
PMC: 3282732.
DOI: 10.1371/journal.pone.0031535.
View
14.
Robertson S, Messer R, Carmody A, Hasenkrug K
. In vitro suppression of CD8+ T cell function by Friend virus-induced regulatory T cells. J Immunol. 2006; 176(6):3342-9.
DOI: 10.4049/jimmunol.176.6.3342.
View
15.
Rohde G, Stenglein S, Prozesky H, Manudhane G, Sandulescu O, Bauer M
. Efficacy and safety of zapnometinib in hospitalised adult patients with COVID-19 (RESPIRE): a randomised, double-blind, placebo-controlled, multicentre, proof-of-concept, phase 2 trial. EClinicalMedicine. 2023; 65:102237.
PMC: 10725048.
DOI: 10.1016/j.eclinm.2023.102237.
View
16.
Laure M, Hamza H, Koch-Heier J, Quernheim M, Muller C, Schreiber A
. Antiviral efficacy against influenza virus and pharmacokinetic analysis of a novel MEK-inhibitor, ATR-002, in cell culture and in the mouse model. Antiviral Res. 2020; 178:104806.
DOI: 10.1016/j.antiviral.2020.104806.
View
17.
Hashiguchi M, Hachimura S, Ametani A, Kaminogawa S
. Th2 polarization enhanced by oral administration of higher doses of antigen. Cytotechnology. 2008; 33(1-3):237-45.
PMC: 3466708.
DOI: 10.1023/A:1008102304740.
View
18.
Schrader T, Dudek S, Schreiber A, Ehrhardt C, Planz O, Ludwig S
. The clinically approved MEK inhibitor Trametinib efficiently blocks influenza A virus propagation and cytokine expression. Antiviral Res. 2018; 157:80-92.
DOI: 10.1016/j.antiviral.2018.07.006.
View
19.
Schreiber A, Viemann D, Schoning J, Schloer S, Mecate Zambrano A, Brunotte L
. The MEK1/2-inhibitor ATR-002 efficiently blocks SARS-CoV-2 propagation and alleviates pro-inflammatory cytokine/chemokine responses. Cell Mol Life Sci. 2022; 79(1):65.
PMC: 8747446.
DOI: 10.1007/s00018-021-04085-1.
View
20.
Rushbrook S, Ward S, Unitt E, Vowler S, Lucas M, Klenerman P
. Regulatory T cells suppress in vitro proliferation of virus-specific CD8+ T cells during persistent hepatitis C virus infection. J Virol. 2005; 79(12):7852-9.
PMC: 1143649.
DOI: 10.1128/JVI.79.12.7852-7859.2005.
View